Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
ADMA BIOLOGICS, INC. (ADMA)
|
Add to portfolio |
|
|
|
| Price: |
$1.43
| | Metrics |
| OS: |
224.9
|
M
| |
-27
|
% ROE
|
| Market cap: |
$322
|
M
| |
-7
|
% ROIC
|
|
Net debt:
|
$78.8
|
M
| |
|
|
|
EV:
|
$400
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($8.7)
|
M
| |
|
|
|
EBIT
|
($16.7)
|
M
| |
|
|
| EPS |
($0.20)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 154.1 | 80.9 | 42.2 | 29.3 | 17.0 | 22.8 | 10.7 | 7.2 |
| Revenue growth | 90.4% | 91.7% | 43.9% | 72.8% | -25.4% | 113.5% | 48.5% | 21.3% |
| Cost of goods sold | 118.8 | 79.8 | 61.3 | 39.5 | 42.2 | 29.2 | 6.4 | 4.3 |
| Gross profit | 35.3 | 1.2 | -19.1 | -10.2 | -25.2 | -6.4 | 4.3 | 2.9 |
| Gross margin | 22.9% | 1.4% | -45.2% | -34.6% | -148.4% | -28.1% | 40.3% | 39.9% |
| Selling, general and administrative | 52.5 | 42.9 | 35.1 | | | | | |
| Research and development | 3.6 | 3.6 | 5.9 | 2.3 | 3.9 | 5.6 | 7.7 | 7.0 |
| General and administrative | | | | 25.9 | 22.5 | 18.8 | 8.5 | 6.7 |
| EBITA | -38.6 | -57.7 | -64.2 | -40.6 | -59.4 | -37.2 | -17.3 | -15.5 |
| EBITA margin | -25.1% | -71.2% | -152.1% | -138.3% | -350.0% | -163.6% | -162.6% | -216.1% |
| Amortization of intangibles | 0.7 | 0.7 | 0.7 | 0.8 | 0.8 | 1.2 | | |
| EBIT | -39.4 | -58.4 | -64.9 | -41.4 | -60.3 | -38.5 | -17.3 | -15.5 |
| EBIT margin | -25.5% | -72.1% | -153.8% | -141.1% | -354.9% | -169.0% | -162.6% | -216.1% |
| Pre-tax income | -65.9 | -71.6 | -75.7 | -48.3 | -65.7 | -43.8 | -19.5 | -18.0 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -65.9 | -71.6 | -75.7 | -48.3 | -65.7 | -43.8 | -19.5 | -18.0 |
| Net margin | -42.8% | -88.5% | -179.4% | -164.5% | -387.1% | -192.3% | -183.1% | -250.4% |
| |
| Diluted EPS | ($0.33) | ($0.51) | ($0.88) | ($0.89) | ($1.45) | ($1.91) | ($1.61) | ($1.73) |
| Shares outstanding (diluted) | 197.9 | 139.6 | 86.1 | 54.3 | 45.2 | 22.9 | 12.2 | 10.4 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|